SCHEMBL456020

SCHEMBL456020

C=CCNC(=S)NN=C1Nc2ccc([N+](=O)[O-])cc2C1=O

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.51
ALDH1A1 P00352 2/20 0.51
CAPN9 O14815 1/20 0.45
CASP3 P42574 1/20 0.45
MAPT P10636 4/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CTSL P07711 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
SIRT2 Q8IXJ6 1/20 0.38
EGFR P00533 1/20 0.37
CHIA Q9BZP6 1/20 0.37
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NOX4 Q9NPH5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL457126 0.81 ALDH1A1 (0.51) LMNAALDH1A1CAPN9CASP3MAPT
SCHEMBL455445 0.80 ALDH1A1 (0.42) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL457611 0.77 ALDH1A1 (0.47) LMNAALDH1A1CAPN9CASP3MAPT
SCHEMBL455908 0.76 RRM1 (0.44) LMNAALDH1A1CAPN9CASP3MAPT
SCHEMBL455700 0.72 ALDH1A1 (0.47) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL469858 0.68 CA1 (0.54) LMNAALDH1A1CAPN9CASP3MAPT
SCHEMBL469972 0.67 TDP1 (0.43) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL469856 0.67 ALDH1A1 (0.51) LMNAALDH1A1CAPN9CASP3MAPT
5-Nitroisatin SCHEMBL455170 0.65 CAPN9 (1.00) ALDH1A1CAPN9CASP3MEN1KMT2A
5-Nitroisatin SCHEMBL29497975 0.65 CAPN9 (1.00) ALDH1A1CAPN9CASP3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012033601-A1 THIOSEMICARBAZONES WITH MDR1 - INVERSE ACTIVITY THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 2012-03-15 WO disclosed
EP-2240175-A2 COMPOUNDS WITH MDR1-INVERSE ACTIVITY The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) 2010-10-20 EP disclosed
WO-2009102433-A2 COMPOUNDS WITH MDR1-INVERSE ACTIVITY THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2009-08-20 WO disclosed